FDA Approves Rituximab Biosimilar for NHL, CLL, GPA, and MPA

Retrieved on: 2020-12-17 21:51:09

Tags for this article:

Medical specialties

Clinical medicine

Medicine

Orphan drugs

Rituximab

Microscopic polyangiitis

Chronic lymphocytic leukemia

Granulomatosis with polyangiitis

Click the tags to see associated articles and topics

FDA Approves Rituximab Biosimilar for NHL, CLL, GPA, and MPA. View article details on hiswai:

Excerpt

The FDA has approved rituximab-arrx, a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma (<b>NHL</b>), ...

Article found on: www.onclive.com

View Original Article